Production (Stage)
Appili Therapeutics Inc.
APLI.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 142.42% | 31.28% | 52.94% | -41.51% | -630.80% |
| Total Depreciation and Amortization | -24.14% | 38.10% | -16.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.45% | 107.62% | -68.54% | 545.88% | 186.27% |
| Change in Net Operating Assets | 76.50% | -212.43% | 744.34% | -80.58% | 33.54% |
| Cash from Operations | 328.04% | -205.37% | 410.78% | 71.51% | -282.00% |
| Capital Expenditure | 100.00% | 58.33% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 58.33% | -- | -- | -- |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -62.68% | -3.76% | 37.85% | -69.17% | 9.96% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -26.15% | 20.25% | 13.30% | 27.97% | -46.63% |
| Cash from Financing | -46.90% | 7.94% | -112.74% | 749.08% | -13.06% |
| Foreign Exchange rate Adjustments | 1,357.58% | 1,200.00% | -200.00% | 142.86% | -600.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 312.19% | -228.26% | 76.57% | 140.07% | -347.60% |